BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Roche (RHHBY)'s RoActemra Wins U.K. Backing for More Arthritis Patients


10/7/2011 7:22:27 AM

Roche Holding AG (ROG) won the backing of the U.K. National Institute for Health and Clinical Excellence for the RoActemra rheumatoid arthritis drug after agreeing to provide a discount to the state-run medical system. RoActemra may be used at additional stages of treating the disease under new draft treatment guidelines, according to an e- mailed statement from the agency, known as NICE. Roche, based in Basel, Switzerland, must provide a discount on the medicine, which costs 9,295 pounds ($14,225) a year for a patient weighing about 70 kilograms (154 pounds). The level of the discount will remain confidential, NICE said.

Read at Bloomberg

Bloomberg
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES